|
[1]SZCZEPANIAK LS, NURENBERG P, LEONARD D, et al.Magnetic resonance spectroscopy to measure hepatic triglyceride content:prevalence of hepatic steatosis in the general population[J].Am J Physiol Endocrinol Metab, 2005, 288 (2) :e462-e468.
|
|
[2]WEI HF, JI G, ZHENG PY.Study of standardizat ion of syndrome diagnosis:an analysis of current status[J].J Chin Integr Med, 2007, 5 (2) :115-121. (in Chinese) 魏华凤, 季光, 郑培永.证候诊断规范化研究的现状分析[J].中西医结合学报, 2007, 5 (2) :115-121.
|
|
[3]ZHANG BL, KANG LY, XIANG YZ.Several questions about efficacy evaluation of clinical research on new drugs of Chinese materia medica[J].Chin J New Clin Rem, 2007, 26 (11) :861-863. (in Chinese) 张伯礼, 康立源, 项耀祖.中药新药临床试验中有关疗效评价若干问题的思考[J].中国新药与临床杂志, 2007, 26 (11) :861-863.
|
|
[4]BEATON MD, CHAKRABARTI S, LEVSTIK M, et al.Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther, 2013, 37 (7) :720-729.
|
|
[5]ZHANG XD, PEI XZ, DA HY.Declaration of new Chinese medicine treatment of fatty liver and related issues discussed in recent years[J].Tradit Chin Drug Res Clin Pharmacol, 2009, 20 (2) :180-182. (in Chinese) 张晓东, 裴小静, 笪红远.近年治疗脂肪肝中药新药申报概况及相关问题探讨[J].中药新药与临床药理, 2009, 20 (2) :180-182.
|
|
[6]MEHTA SR.Advances in the treatment of nonalcoholic fatty liver disease[J].Ther Adv Endocrinol Metab, 2010, 1 (3) :101-115.
|
|
[7]PARKER HM, JOHNSON NA, BURDON CA, et al.Omega-3supplementation and non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].J Hepatol, 2012, 56 (4) :944-951.
|
|
[8]CUSSONS AJ, WATTS GF, MORI TA, et al.Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome:a randomized controlled trial employing proton magnetic resonance spectroscopy[J].J Clin Endocrinol Metab, 2009, 94 (10) :3842-3848.
|
|
[9]BASARANOGLU M, ACBAY O, SONSUZ A.A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis[J].J Hepatol, 1999, 31 (2) :384.
|
|
[10]LEUSCHNER UF, LINDENTHAL B, HERRMANN G, et al;NASH Study Group.High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis:a double-blind, randomized, placebo-controlled trial[J].Hepatology, 2010, 52 (2) :472-479.
|
|
[11]RATZIU V, de LEDINGHEN V, OBERTI F, et al.A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis[J].J Hepatol, 2011, 54 (5) :1011-1019.
|
|
[12]PAMUK GE, SONSUZ A.N-acetylcysteine in the treatment of nonalcoholic steatohepatitis[J].J Gastroenterol Hepatol, 2003, 18 (10) :1220-1221.
|
|
[13]BUGIANESI E, GENTILCORE E, MANINI R, et al.A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease[J].Am J Gastroenterol, 2005, 100 (5) :1082-1090.
|
|
[14]RATZIU V, GIRAL P, JACQUEMINET S, et al.Rosiglitazone for nonalcoholic steatohepatitis:one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial[J].Gastroenterology, 2008, 135 (1) :100-110.
|
|
[15]KELLOW NJ, SAVIGE GS.Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction:a systematic review[J].Eur J Clin Nutr, 2013, 67 (3) :239-248.
|
|
[16]AITHAL GP, THOMAS JA, KAYE PV, et al.Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J].Gastroenterology, 2008, 135 (4) :1176-1184.
|
|
[17]OMER Z, CETINKALP S, AKYILDIZ M, et al.Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease[J].Eur J Gastroenterol Hepatol, 2010, 22 (1) :18-23.
|
|
[18]JI G.Pay attention to insulin resistance in chronic liver diseases[J].J Chin Integr Med, 2010, 8 (1) :1-6. (in Chinese) 季光.重视慢性肝病中的胰岛素抵抗[J].中西医结合学报, 2010, 8 (1) :1-6.
|
|
[19]YU L.Action mechanism of traditional Chinese medicines for reducing insulin resistance in patients with type 2 diabetes[J].J Changchun Univ Tradit Chin Med, 2012, 28 (2) :79-81. (in Chinese) 俞露.中医药改善Ⅱ型糖尿病胰岛素抵抗机制研究[J].长春中医药大学学报, 2012, 28 (2) :79-81.
|
|
[20]PROMRAT K, KLEINER DE, NIEMEIER HM, et al.Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis[J].Hepatology, 2010, 51 (1) :121-129.
|
|
[21]DUFOUR JF, ONETA CM, GONVERS JJ, et al.Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis[J].Clin Gastroenterol Hepatol, 2006, 4 (12) :1537-1543.
|
|
[22]WONG VW, VERGNIOL J, WONG GL, et al.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease[J].Hepatology, 2010, 51 (2) :454-462.
|
|
[23]HARRISON SA, OLIVER D, ARNOLD HL, et al.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease[J].Gut, 2008, 57 (10) :1441-1447.
|
DownLoad: